Gilead Sciences Inc.: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors
• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• Gilead Sciences: PharmaVitae forecasts at a glance
• Strategic insight
  • (Untitled sub-section)
  • Gilead looks outside to diversify and spread risk
• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Product developments
• Deals and alliances
  • Technology deals
• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• M&A history
  • Myogen
  • Corus
  • Raylo Chemicals
  • CV Therapeutics

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14
• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
  • Launch/core/expiry configuration, 2008 - 14
• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
• Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Infectious diseases
  • Atripla
  • Truvada
  • Viread
  • Truvada + rilpivirine
• Cardiovascular
  • Letairis

APPENDIX

• R&D pipeline
• References
  • Datamonitor reports
• Abbreviations

TABLES

• Table: Gilead - PharmaVitae forecasts at a glance
• Table: Gilead' s HIV franchise, 2008 - 14 ($m)
• Table: Gilead key product developments, 2009
• Table: Gilead product deals and alliances, 2009
• Table: Gilead technology deals and alliances, 2009
• Table: Gilead M&A activity, 2009
• Table: Gilead company announcements, 2009
• Table: Gilead future product milestones, 2009 - 11
• Table: Gilead product portfolio overview ($m), 2002 - 08
• Table: Gilead product portfolio overview ($m), 2008 - 14
• Table: Gilead prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: Gilead prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: Gilead launch portfolio overview ($m), 2008 - 14
• Table: Gilead core portfolio overview ($m), 2008 - 14
• Table: Gilead expiry portfolio overview ($m), 2008 - 14
• Table: Gilead prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: Gilead prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total Gilead sales by business unit ($m), 2002 - 08
• Table: Gilead operating revenue/cost analysis ($m), 2002 - 08
• Table: Gilead operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: Gilead operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: Gilead operating revenue/cost analysis ($m), 2008 - 14
• Table: Key products overview
• Table: Atripla: overview
• Table: Atripla: sales forecast ($m), 2008 - 14
• Table: Truvada: overview
• Table: Truvada: sales forecast ($m), 2008 - 14
• Table: Viread: overview
• Table: Viread: sales forecast ($m), 2008 - 14
• Table: Truvada + rilpivirine: overview
• Table: Truvada + rilpivirine: sales forecast ($m), 2008 - 14
• Table: Letairis: overview
• Table: Letairis: sales forecast ($m), 2008 - 14
• Table: Gilead Sciences R&D pipeline (Phase I - registration)

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Gilead' s financial performance ($m), 2002 - 14
• Figure: Sales of the leading HIV therapy players, 2002 - 14 ($m)
• Figure: Gilead prescription pharmaceutical sales by source, and therapy area ($m), 2002 - 14
• Figure: Gilead SWOT analysis
• Figure: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Key product sales ($m), 2002 - 14
• Figure: Gilead key sales growth drivers and resistors ($m), 2002 - 08
• Figure: Gilead key sales growth drivers and resistors ($m), 2008 - 14
• Figure: Gilead prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: Gilead prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: Gilead launch/core/expiry configuration ($m), 2008 - 14
• Figure: Gilead prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: Gilead prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Gilead operating revenue/cost analysis ($m), 2002 - 14